Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Daniel, Peter Prof. Dr. (1) Janz, Martin Dr. (7) Kammertöns, Thomas Dr. (4) Kopp, Joachim Dr. (1) Leisegang, Matthias Prof. Dr. rer. nat. (2) Lusatis, Simone (1) Mathas, Stephan Dr. (9) Nguyen, Tam Hoai Dr. (1) Pezzutto, Antonio Prof. Dr. (2) Selbach, Matthias Prof. Dr. (7) Uckert, Wolfgang Prof. Dr. (3) Willimsky, Gerald Dr. (4) Wollert-Wulf, Brigitte (2) (-) Blankenstein, Thomas Prof. Dr. (16) (-) Molekulare Immunologie und Gentherapie (16) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) (-) 2004 (8) 2005 (10) (-) 2006 (1) 2007 (5) 2008 (5) 2009 (2) (-) 2010 (7) 2011 (5) 2012 (6) 2013 (11) 2014 (4) 2015 (3) 2016 (4) 2017 (6) 2018 (4) 2019 (6) 2021 (4) 2022 (6) 2023 (5) 2024 (1) 16 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Molekulare Immunologie und Gentherapie 200420062010 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel 01. März 2010 / J Mol Med Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia S. Shalapour C. Eckert K. Seeger M. Pfau J. Prada G. Henze T. Blankenstein T. Kammertoens 15. März 2010 / J Immunol In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance C. Buschow J. Charo K. Anders C. Loddenkemper A. Jukica W. Alsamah C. Perez G. Willimsky T. Blankenstein 01. Januar 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein 01. Januar 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto 01. August 2004 / Immunity CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions L. Ohl M. Mohaupt N. Czeloth G. Hintzen Z. Kiafard J. Zwirner T. Blankenstein G. Henning R. Foerster 01. Juli 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein 01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert 01. Januar 2004 / Int J Cancer CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells J.A. Lindencrona S. Preiss T. Kammertoens T. Schueler M. Piechocki W.Z. Wei B. Seliger T. Blankenstein R. Kiessling 01. Januar 2004 / J Immunol Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-γ pathway but not IL-12 or IL-18 T.H. Wu C.N. Pabin Z.H. Qin T. Blankenstein M. Philip J. Dignam K. Schreiber H. Schreiber Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
01. März 2010 / J Mol Med Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia S. Shalapour C. Eckert K. Seeger M. Pfau J. Prada G. Henze T. Blankenstein T. Kammertoens
15. März 2010 / J Immunol In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance C. Buschow J. Charo K. Anders C. Loddenkemper A. Jukica W. Alsamah C. Perez G. Willimsky T. Blankenstein
01. Januar 2004 / J Immunol Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin alpha and in the combined absence of functional B and T cells H.J. Kim T. Kammertoens M. Janke O. Schmetzer Z. Qin C. Berek T. Blankenstein
01. Januar 2004 / Gene Ther Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization J. Westermann T. Nguyen-Hoai A. Mollweide G. Richter O. Schmetzer H.J. Kim T. Blankenstein B. Doerken A. Pezzutto
01. August 2004 / Immunity CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions L. Ohl M. Mohaupt N. Czeloth G. Hintzen Z. Kiafard J. Zwirner T. Blankenstein G. Henning R. Foerster
01. Juli 2004 / Eur J Immunol Dual T cell receptor T cells with two defined specificities mediate tumor suppression via both receptors M. Gladow W. Uckert T. Blankenstein
01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
01. Januar 2004 / Int J Cancer CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells J.A. Lindencrona S. Preiss T. Kammertoens T. Schueler M. Piechocki W.Z. Wei B. Seliger T. Blankenstein R. Kiessling
01. Januar 2004 / J Immunol Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-γ pathway but not IL-12 or IL-18 T.H. Wu C.N. Pabin Z.H. Qin T. Blankenstein M. Philip J. Dignam K. Schreiber H. Schreiber